New publication about the incidence and management of patients with methotrexate delayed elimination

//New publication about the incidence and management of patients with methotrexate delayed elimination

New publication about the incidence and management of patients with methotrexate delayed elimination

We are very pleased to share a new publication of which OMAKASE is a coauthor: a study to determine the incidence and management of patients with methotrexate delayed elimination in the clinical practice using the Delphi methodology. These results are the first evidence on the epidemiology and management of HDMTX-induced AKI in Spain.

High-dose methotrexate (HDMTX), used in the treatment of some malignancies, is usually safe but may cause acute kidney injury (AKI), a severe and life-threatening condition. Ten experts from different Spanish hospitals participated in this Delphi Study with the objective of determining the epidemiology and clinical management of methotrexate delayed elimination and its associated complications in the clinical practice.

The study has been published in the Journal of Oncology Pharmacy Practice and is available here:

Incidence and management of patients with methotrexate delayed elimination in the clinical practice: A Delphi study – PubMed (nih.gov)

2022-02-15T13:28:45+00:00February 15th, 2022|Articles|